Radzina Maija, Saule Laura, Mamis Edgars, Pajuste Elina, Koester Ulli, Cocolios Thomas Elias, Proskurins Jevgenijs, Kalnina Patricija, Zabolockis Rudolfs Janis, Palskis Kristaps, Talip Zeynep, Jensen Mikael, Duchemin Charlotte, Baatout Sarah, Leufgen Kirsten, Stora Thierry
University of Latvia, Riga, Latvia.
CERN, Geneva, Switzerland.
EJNMMI Radiopharm Chem. 2024 Dec 18;9(1):85. doi: 10.1186/s41181-024-00318-3.
In the field of medical and scientific research, radionuclides are used to investigate various physiological and pathological processes. PRISMAP - the European medical radionuclide programme was created to bring together production facilities including intense neutron sources, an isotope mass separation facility, high-power accelerators, biomedical research institutes, and hospitals to support medical research. The aim of this article is to introduce readers with the current status of innovative radionuclides in Europe.
A survey was created targeting the latest trends mainly focused on the demand, the production and the distribution of non-routinely used medical radionuclides for use in research, and for pre-clinical and clinical trials. This survey has been disseminated through the PRISMAP community. 16 of 104 respondents were working in the field of radionuclide production. The data found common aspects from all producer-facility respondents: the biggest challenge for the producers is the availability of target materials, which goes hand-in-hand with their purity/enrichment grade. The results show that there are sufficient national or international distribution routes and methods established, although having reported challenges due to legislation constraints, especially for novel radionuclides.
Thanks to a questionnaire distributed by the PRISMAP consortium, the current status in radionuclides production was identified. Understanding the current status of radionuclide production is essential for assessing the continent's capabilities and addressing the burgeoning demands for cutting-edge medical radionuclides.
在医学和科学研究领域，放射性核素被用于研究各种生理和病理过程。PRISMAP（欧洲医用放射性核素计划）旨在汇聚包括强中子源、同位素质量分离设施、高功率加速器、生物医学研究机构和医院在内的生产设施，以支持医学研究。本文旨在向读者介绍欧洲创新放射性核素的现状。
针对主要聚焦于非常规使用的医用放射性核素在研究、临床前和临床试验中的需求、生产及分配的最新趋势开展了一项调查。该调查已在PRISMAP群体中传播。104名受访者中有16人从事放射性核素生产领域的工作。数据发现了所有生产设施受访者的共同之处：生产商面临的最大挑战是靶材料的可用性，这与其纯度/富集等级密切相关。结果表明，尽管由于立法限制（尤其是对于新型放射性核素）报告了一些挑战，但已建立了足够的国家或国际分配途径和方法。
通过PRISMAP联盟分发的一份调查问卷，确定了放射性核素生产的现状。了解放射性核素生产的现状对于评估欧洲大陆的能力以及满足对前沿医用放射性核素迅速增长的需求至关重要。
